FDA Approves CELLCEPT — Genentech, Inc.

Genentech's (NYSE: DNA) CELLCEPT received FDA approval on August 12, 1998, for the intravenous formulation of mycophenolate mofetil hydrochloride, an approval that broadened the drug's market potential by enabling IV delivery for kidney transplant patients necessitating oral intake complications.